奥马珠单抗对过敏性鼻炎合并中度持续性支气管哮喘的疗效观察  

Observation of therapeutic efficacy of omalizumab on allergic rhinitis complicated by moderate persistent bronchial asthma

作　　者：马东波[1] 王喜玲 张辉[1] 伍冬冬 史向蕊 王梦瑶 吴秋歌[1] Ma Dongbo;Wang Xiling;Zhang Hui;Wu Dongdong;Shi Xiangrui;Wang Mengyao;Wu Qiuge(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院呼吸与危重症医学科,郑州450052

出　　处：《中国实用医刊》2024年第14期76-80,共5页Chinese Journal of Practical Medicine

基　　金：河南省医学科技攻关省部共建重点项目(SBGJ202102166)。

摘　　要：目的探讨奥马珠单抗对过敏性鼻炎合并中度持续性支气管哮喘的临床疗效。方法回顾性分析于郑州大学第一附属医院接受治疗的167例过敏性鼻炎合并中度持续支气管哮喘患者的临床资料。167例患者中,82例给予中剂量ICS/LABA类药物(布地奈德福莫特罗吸入粉雾剂或沙美特罗替卡松吸入气雾剂)联合奥马珠单抗治疗者为观察组,85例给予高剂量布地奈德福莫特罗吸入粉雾剂或沙美特罗替卡松吸入气雾剂治疗者为对照组。评估两组各时间点相关检测指标[血免疫球蛋白E(IgE)、外周血嗜酸性粒细胞(EOS),呼出气一氧化氮(FeNO)、哮喘控制测试评分(ACT)]、肺功能指标[第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占预计值的百分比(FEV1%pred)、第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)]及鼻部症状缓解情况。结果对照组治疗3个月IgE、FeNO水平低于治疗前,ACT、FEV1、FEV1/FVC水平高于治疗前(P<0.05),对照组治疗后12个月IgE、FeNO水平低于治疗前,ACT、FEV1、FEV1%pred、FEV1/FVC水平高于治疗前(P<0.05);对照组治疗12个月FeNO水平低于治疗3个月,FEV1、FEV1%pred、FEV1/FVC水平高于治疗3个月,鼻部症状缓解情况优于治疗3个月(P<0.05)。观察组治疗3、12个月IgE及FeNO水平低于治疗前,ACT、FEV1、FEV1%pred、FEV1/FVC水平高于治疗前(P<0.05);观察组治疗12个月IgE、FeNO水平低于治疗后3个月,ACT、FEV1、FEV1%pred、FEV1/FVC水平高于治疗后3个月,鼻部症状缓解优于治疗后3个月(P<0.05)。治疗3个月,观察组FeNO水平低于对照组,ACT、FEV1、FEV1/FVC水平高于对照组(P<0.05);治疗12个月,观察组IgE、FeNO水平低于对照组,ACT、FEV1、FEV1%pred、FEV1/FVC水平高于对照组,鼻部症状缓解优于对照组(P<0.05)。结论高剂量ICS/LABA类药物单独使用,以及中剂量ICS/LABA类药物联合奥马珠单抗于治疗3、12个月,患者呼吸功能及鼻部症状均有所缓解,但联合用药�ObjectiveTo investigate the therapeutic efficacy of omalizumab on allergic rhinitis complicated by moderate persistent bronchial asthma.MethodsThe clinical data of 167 patients with allergic rhinitis complicated by moderate persistent bronchial asthma who were treated in the First Affiliated Hospital of Zhengzhou University were retrospectively analyzed.Among the 167 patients,82 cases treated with medium-dose ICS/LABA drugs(budesonide formoterol inhalation powder aerosol or salmeterol ticasone inhalation aerosol)combined with omalizumab were selected as the observation group,and 85 cases treated with high-dose budesonide formoterol inhalation powder aerosol or salmeterol ticasone inhalation aerosol were selected as the control group.The relevant test indicators such as blood immunoglobulin E(IgE),peripheral blood eosinophils(EOS),exhaled nitric oxide(FeNO)and asthma control test(ACT)score,pulmonary function indicators including forced expiratory volume in 1 second(FEV1),forced expiratory volume in 1 second percent predicted(FEV1%pred),forced expiratory volume in 1 second to forced vital capacity(FEV1/FVC),and remission of nasal symptoms of the two groups were compared.ResultsIn the control group,the 3-month postoperative levels of IgE and FeNO were lower than those before treatment,while the 3-month postoperative levels of ACT,FEV1 and FEV1/FVC were higher than those before treatment(P<0.05);in the control group,the 12-month postoperative levels of IgE and FeNO were lower than those before treatment,moreover,the 12-month postoperative levels of ACT,FEV1,FEV1%pred and FEV1/FVC were higher than those before treatment(P<0.05).In the control group,the levels of FeNO after 12 months of treatment was lower,while the levels of FEV1,FEV1%pred and FEV1/FVC after 12 months of treatment were higher,and the remission of nasal symptoms was better compared with these indexes after 3 months of treatment(P<0.05).In the observation group,the levels of IgE and FeNO after 3 and 12 months of treatment decreased compared with those i

关 键 词：奥马珠单抗 过敏性鼻炎 支气管哮喘 临床疗效 

分 类 号：R765.21[医药卫生—耳鼻咽喉科] R562.25[医药卫生—临床医学]